KRAS and neoplasm: To compare the anti-tumor effect of RGS and fluoropyrimidine (5-FU)/irinotecan/oxaliplatin-based standard chemotherapy in advanced CRC, PDX models derived from a KRAS-mutant patient who was primarily resistant to standard therapy were used in our study.